Back to discover
Drug

Mannitol

Approved · EMA
Emerging researchLate-stage development
Also known as Bronchitol, D-(-)-Mannitol, D-Mannitol, Manna Sugar+10 more

Bronchitol, D-(-)-Mannitol, D-Mannitol, Manna Sugar, Mannitol, Injectable, Mannitol-Sorbitol, Osmitrol, Resectisol, Manitol, Mannit, Mannite, (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol, (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol, Mannitolum.

2
Research papers
10
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Budesonide as a Treatment for Low-grade Duodenal Inflammation in Functional Dyspepsia

Clinical trial2026-05-31Primary completion · ClinicalTrials.gov

Propofol Level at TCI During Mannitol

Clinical trial2025-10-20Primary completion · ClinicalTrials.gov

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Clinical trial2025-08-30Primary completion · ClinicalTrials.gov

Approval: Bronchitol (EMA)

Regulatory2012-04-13EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Mannitol
Aliases & brands
BronchitolD-(-)-MannitolD-MannitolManna SugarMannitol, InjectableMannitol-SorbitolOsmitrolResectisolManitolMannitMannite(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexolMannitolum
RxNorm CUI
6628
ChEMBL ID
CHEMBL689
ATC codes
B05CX04B05BC01A06AD16R05CB16V04CX04
UNII
3OWL53L36A
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2012-04-13
Latest approval
2012-04-13
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2012-04-13Approval
Approval: Bronchitol (EMA)

Indication: Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

82 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
82
registered trials across all phases
LATEST COMPLETION 2026
10
Active studies
8
Recruiting
48
Late-stage (III+)
47
Completed
25
Discontinued
PHASE DISTRIBUTIONn = 82
Early Phase 13Phase 17Phase 1 / 29Phase 215Phase 2 / 36Phase 315Phase 49Phase N / A18

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20032023
Major research themes2
Endocrinology1Human Growth Hormone1
Journals, researchers & institutions
Top journals
  • Medicine1
  • The Plant cell1
Leading researchers
  • Abe H1
  • Abe I1
  • Abe M1
  • Fujita Y1
  • Ito T1
  • Kobayashi K1
  • Koga M1
  • Kudo T1
Leading institutions
free-text, unnormalised
  • Clinical Research Support Center1
  • Fukuoka University1
  • Fukuoka University Chikushi Hospital1
  • Japan International Research Center for Agricultural Sciences1
  • Nagasaki Prefecture Iki Hospital1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Frequently co-studied with Mannitol in the research literature.

1 shared paper

Frequently co-studied with Mannitol in the research literature.

1 shared paper

Frequently co-studied with Mannitol in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.